Unknown PHASE1 INTERVENTIONAL 1-arm NCT02580747

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso

Clinical Study of Chimeric Mesothelin Antigen Receptor-modified T Cells in Relapsed and/or Chemotherapy Refractory Malignancies

Sponsor: Chinese PLA General Hospital

Conditions Endometrial Cancer Malignant Mesothelioma Other Mesothelin Positive Tumors Ovarian Tumor Pancreatic Cancer Triple Negative Breast Cancer

Interventions anti-meso-CAR vector transduced T cells

Updated 5 times since 2017 Last updated: Oct 19, 2015 Started: Oct 31, 2015 Primary completion: Nov 30, 2017 Completion: Nov 30, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Endometrial Cancer and Malignant Mesothelioma and is currently ongoing. Chinese PLA General Hospital leads this study, which shows 5 recorded versions since 2015 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Dec 2018 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jan 2017 — Dec 2018 [monthly]

Recruiting PHASE1

First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chinese PLA General Hospital

Data source: Chinese PLA General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China